Lycia Therapeutics, Inc.

AltruBio Inc. took a big step up from its $63m series A venture capital round in 2021 when it announced a series B round totaling up to $225m on 21 May, which will fund ongoing and planned Phase IIa

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Vanda To Pay $100m For Rights To MS The

Targeted protein degradation, or TPD, has been steadily gaining attention in recent years as a highly promising new drug development strategy that has already attracted significant investment and big

Targeted protein degradation, or TPD, has been steadily gaining attention in recent years as a highly promising new drug development strategy that has already attracted significant investment and big